BioPharma Credit (BPCR) Competitors GBX 0.87 0.00 (-0.46%) As of 05:44 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendInsider TradesBuy This Stock BPCR vs. PCT, ATST, PHLL, ABDN, EMG, 3IN, BUR, JGGI, RCP, and BPTShould you be buying BioPharma Credit stock or one of its competitors? The main competitors of BioPharma Credit include Polar Capital Technology Trust (PCT), Alliance Trust (ATST), Petershill Partners (PHLL), abrdn (ABDN), Man Group (EMG), 3i Infrastructure (3IN), Burford Capital (BUR), JPMorgan Global Growth & Income (JGGI), RIT Capital Partners (RCP), and Bridgepoint Group (BPT). These companies are all part of the "asset management" industry. BioPharma Credit vs. Polar Capital Technology Trust Alliance Trust Petershill Partners abrdn Man Group 3i Infrastructure Burford Capital JPMorgan Global Growth & Income RIT Capital Partners Bridgepoint Group BioPharma Credit (LON:BPCR) and Polar Capital Technology Trust (LON:PCT) are both financial services companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, community ranking, profitability, dividends and earnings. Which has stronger valuation and earnings, BPCR or PCT? BioPharma Credit has higher revenue and earnings than Polar Capital Technology Trust. Polar Capital Technology Trust is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioPharma Credit£12.99B0.08£10.42B£0.099.98Polar Capital Technology Trust£1.24B3.02£1.20B£101.863.13 Which has more risk & volatility, BPCR or PCT? BioPharma Credit has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Polar Capital Technology Trust has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Is BPCR or PCT more profitable? Polar Capital Technology Trust has a net margin of 96.56% compared to BioPharma Credit's net margin of 80.20%. Polar Capital Technology Trust's return on equity of 30.54% beat BioPharma Credit's return on equity.Company Net Margins Return on Equity Return on Assets BioPharma Credit80.20% 8.51% 4.98% Polar Capital Technology Trust 96.56%30.54%20.70% Does the MarketBeat Community favor BPCR or PCT? BioPharma Credit received 1 more outperform votes than Polar Capital Technology Trust when rated by MarketBeat users. Likewise, 64.62% of users gave BioPharma Credit an outperform vote while only 64.34% of users gave Polar Capital Technology Trust an outperform vote. CompanyUnderperformOutperformBioPharma CreditOutperform Votes8464.62% Underperform Votes4635.38% Polar Capital Technology TrustOutperform Votes8364.34% Underperform Votes4635.66% Does the media prefer BPCR or PCT? In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled Polar Capital Technology Trust'saverage media sentiment score. Company Overall Sentiment BioPharma Credit Neutral Polar Capital Technology Trust Neutral Do insiders and institutionals believe in BPCR or PCT? 41.5% of BioPharma Credit shares are owned by institutional investors. Comparatively, 43.2% of Polar Capital Technology Trust shares are owned by institutional investors. 6.2% of BioPharma Credit shares are owned by insiders. Comparatively, 1.2% of Polar Capital Technology Trust shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryPolar Capital Technology Trust beats BioPharma Credit on 7 of the 13 factors compared between the two stocks. Remove Ads Get BioPharma Credit News Delivered to You Automatically Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPCR vs. The Competition Export to ExcelMetricBioPharma CreditAsset Management IndustryFinancial SectorLON ExchangeMarket Cap£1.04B£1.17B£4.28B£2.60BDividend Yield13.43%4.41%4.18%4.95%P/E Ratio9.9827.0916.01152.77Price / Sales0.082,289.551,718.75282,666.96Price / Cash1.1960.8148.9727.91Price / Book0.011.123.364.60Net Income£10.42B£258.33M£1.27B£5.77B7 Day Performance-1.13%0.38%0.86%-0.24%1 Month Performance1.62%-1.59%6.82%4.15%1 Year Performance-2.23%6.03%11.33%133.38% BioPharma Credit Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPCRBioPharma CreditN/AGBX 0.87-0.5%N/A-2.2%£1.04B£12.99B9.94N/APositive NewsPCTPolar Capital Technology TrustN/AGBX 305-0.7%N/AN/A£3.60B£1.24B2.99120Positive NewsHigh Trading VolumeATSTAlliance TrustN/AN/AN/AN/A£3.58B£652.76M600.003PHLLPetershill Partners1.2694 of 5 starsGBX 240flatGBX 245.33+2.2%+42.8%£3.26B£706.00M9.74N/AHigh Trading VolumeABDNabrdn0.8422 of 5 starsGBX 174.90-0.4%GBX 163.50-6.5%+17.5%£3.13B£1.49B9.944,719High Trading VolumeEMGMan Group2.7798 of 5 starsGBX 210.20+0.4%GBX 291.17+38.5%-19.5%£3.03B£1.69B9.921,790High Trading Volume3IN3i InfrastructureN/AGBX 316.50+0.2%N/A-3.7%£2.92B£374M832.89N/ADividend IncreaseNews CoverageHigh Trading VolumeBURBurford Capital2.3135 of 5 starsGBX 1,058flatGBX 1,600+51.2%-9.6%£2.91B£299.55M18.93140High Trading VolumeJGGIJPMorgan Global Growth & IncomeN/AGBX 544flatN/A-1.4%£2.80B£660.56M4.48N/ARCPRIT Capital PartnersN/AGBX 1,890-0.4%N/A+8.3%£2.72B£103.46M16.3462High Trading VolumeBPTBridgepoint Group1.0979 of 5 starsGBX 321+1.8%GBX 334+4.0%+26.1%£2.65B£272.35M58.31391Gap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Polar Capital Technology Trust Alternatives Alliance Trust Alternatives Petershill Partners Alternatives abrdn Alternatives Man Group Alternatives 3i Infrastructure Alternatives Burford Capital Alternatives JPMorgan Global Growth & Income Alternatives RIT Capital Partners Alternatives Bridgepoint Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:BPCR) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPharma Credit Please log in to your account or sign up in order to add this asset to your watchlist. Share BioPharma Credit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
